Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/25513| Title: | The Potential for Repurposing Anti-TNF as a Therapy for the Treatment of COVID-19. | Austin Authors: | Robinson, Philip C;Liew, David F L ;Liew, Jean W;Monaco, Claudia;Richards, Duncan;Shivakumar, Senthuran ;Tanner, Helen L;Feldmann, Marc | Affiliation: | Department of Clinical Pharmacology and Therapeutics, Austin Health, Heidelberg, Victoria, Australia Section of Rheumatology, Department of Medicine, Boston University School of Medicine, Boston, MA, USA Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford OX3 7LD, UK Oxford Clinical Trials Research Unit, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford OX3 7LD, UK University of Queensland Faculty of Medicine, Herston, Queensland, Australia Department of Medicine, Royal Brisbane and Women's Hospital, Metro North Hospital and Health Service, Herston, Queensland, Australia Department of Medicine, University of Melbourne, Parkville, Victoria, Australia Kennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford OX3 7LD, UK |
Issue Date: | 3-Dec-2020 | Date: | 2020-12-18 | Publication information: | Med 2020; 1(1): 90-102 | Abstract: | Coronavirus disease 2019 (COVID-19) currently has few effective treatments. Given the uncertainty surrounding the effectiveness and uptake of a vaccine, it is important that the search for treatments continue. An exaggerated inflammatory state is likely responsible for much of the morbidity and mortality in COVID-19. Elevated levels of tumor necrosis factor (TNF), a key pro-inflammatory cytokine, have been shown to be associated with increased COVID-19 mortality. In patients with rheumatoid arthritis, TNF blockade reduces not only biologically active TNF but other pro-inflammatory cytokines important in COVID-19 hyperinflammation. Observational data from patients already on anti-TNF therapy show a reduced rate of COVID-19 poor outcomes and death compared with other immune-suppressing therapies. Anti-TNF has a long history of safe use, including in special at-risk populations, and is widely available. The case to adequately assess anti-TNF as a treatment for COVID-19 is compelling. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/25513 | DOI: | 10.1016/j.medj.2020.11.005 | Journal: | Med | PubMed URL: | 33294881 | Type: | Journal Article | Subjects: | SARS-CoV-2 coronavirus disease-2019 glucocorticoids pandemic tumor necrosis factor COVID-19 |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.